Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Those Chemistry Bloggers | Main | So, How Well Does Winning a Nobel Set You Up? »

October 18, 2010

Merck vs. J&J: Wait For It

Email This Entry

Posted by Derek

We're going to have to wait to find out of the whole Schering-Plough-buys-Merck charade is really going to allow revenue from J&J's Remicade to stay with the merged company. That merged company is known as "Merck", of course, and is run by Merck people from Merck's headquarters, so it's going to be interesting to see how that dispute goes. But although the first arguments have been made before an arbitration board, the decision doesn't look to be made until sometime next year. It sounds as if Merck is already trying to lower expectations, though. . .

Comments (4) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. ty on October 18, 2010 9:38 AM writes...

I couldn't find a reference to the "lower expectations" but I'm pretty sure there's a finance/accounting principle that for SEC traded securities, you are required to lean towards the conservative side for financial projections. This may be an oversimplification, but when litigations are ongoing, firms are required to assume (on their books to varying degrees) that they will lose.

Permalink to Comment

2. Tony on October 18, 2010 4:41 PM writes...

I hope they get burned on this one. Merck used to be a great company and they they pretty much suck. Following the Pfizer model which hasn't raised their stock and will not help Merck either.

Permalink to Comment

3. betalactam on October 18, 2010 7:05 PM writes...

I thought the new company was called Shmerck?

Permalink to Comment

4. Tony on November 6, 2010 6:09 PM writes...

I heard that Derek interviewed at both Merck and J&J and thats how he got the scoop on this article. Anyone know if thats true ?

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Resveratrol Explained. A Little Bit.
Flip That Glucose, Please
Chemists and Biologists, In Detail
Regulatory Hurdles
India's First Drug Isn't India's First Drug
AstraZeneca Shuffles the Top Cards
How Do Drugs Get Into Cells? A Vicious Debate.
Different Worlds: A Last DHFR Paper Thought